ACM Biosciences AG was established in Basel, Switzerland in September 2020. It is dedicated to the development of infectious disease vaccines using the proprietary ACM polymersome platform technology it has licensed from ACM Biolabs Pte Ltd. Its current primary focus is to get a safe, effective and highly manufacturable COVID-19 vaccine through clinical trials.


Dr. Peter Moran

Chief Executive Officer, Member of the Board

PhD, Brown University, USA. Managed the Micro and Nano-systems group of 50 R&D staff in the Singapore research institute where the commercialization of polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. After moving to Switzerland, he started working with Dr Nallani on ACM Biolabs and from 2016 he served as the COO of that company, prior to being appointed as CEO of ACM Biosciences AG.

Dr. Madhavan Nallani

Chief Scientific Officer, Member of the Board

PhD, Jacobs University Bremen, Germany. Spent more than 15 years developing the polymersome technology, including while Professor at NTU, a leading Singapore university which is ranked 13th in the QS World University Rankings. He has translated the science of polymersomes to a technology platform and founded ACM Biolabs in 2013. Since its inception, he was developing overall corporate strategy and day-to-day business operations to establish product portfolio development. He has raised multiple millions of funds from family offices, corporate investors, multinationals and government bodies. He founded ACM’s subsidiary AAVACC Pte Ltd in 2017, establishing its veterinary vaccines portfolio.

Dietrich Joos

Chief Financial Officer, Member of the Board

Master's Degree in Economics and Social Sciences. Managing partner of Independent Capital Group, he is a long-term Life Sciences investor with more than 30 years of experience in asset management. He was Senior Portfolio Manager at Roche and Pharma Analyst at UBS.

Dr. Alexander Breidenbach

Chief Business Officer

Pharmacologist and Business Developer with more than 20 years of partnering, R&D, and management experience in pharma. Doctorate in Veterinary Sciences, EMBA from ESSEC Paris & Mannheim Business School. Expertise in business development as Roche VP and Global Head Neuroscience, Ophthalmology, Rare Diseases Partnering, Deal Team Leader and Due Diligence Director. Global Head Safety Pharmacology at Roche Pharmaceuticals. Senior Pharmacologist at Schwarz Pharma AG.

Dr. Andreas Wallnöfer

Chairman of the Board

Dr. Andreas Wallnöfer, PhD, MBA. Former Global Head of Clinical Research at Roche, and after Roche’s acquisition of Genentech he was appointed as SVP & Head of pRED Development. In 2016 became a General Partner at BioMed Partners, a Swiss & EU Venture Capital firm.

Bruno Heynen

General Counsel, Secretary to the Board

Law degree (lic. iur HSG) from University of St. Gallen. Master degree (LL.M.) in International Business Law from London School of Economics. Swiss attorney-at-law and notary. 30 years of experience in business law: 15 years working for Novartis in different roles, including Head Corporate Law & Governance, Secretary to the Board and to the Executive Committee of Novartis. General Counsel of DHL Air & Ocean, General Counsel of Danzas, Corporate Legal Counsel at Roche, and attorney at Swiss law firm at Froriep Renggli, working from the Zürich and London offices.

Catherine Ammann

Head Admin, CPO

Executive MBA in Human Resources Management from the University of Applied Sciences of Bern. Certificate of Advanced Studies in Compensation & Benefits. In 2013, Catherine founded her own HR Advisory company which is mainly focused on supporting Biotech companies in all HR related matters, currently she advises several Biotech companies as Head HR in an executive function. Held various managerial roles in international companies on local, regional and global level (UBS, Panalpina, Straumann).